Results 151 to 160 of about 7,735 (207)

Successful Treatment of HER2 V659E Mutation-Positive Lung Adenocarcinoma With Trastuzumab Deruxtecan: A Case Report. [PDF]

Thorac Cancer
Nishihara M, Shinno Y, Masui Y, Masuda K, Matsumoto Y, Okuma Y, Yoshida T, Goto Y, Horinouchi H, Yamamoto N, Ohe Y.   +10 more
europepmc   +1 more source

Anti-CA6-DM4 Immunoconjugate SAR566658 [PDF]

, 2020
openaire   +1 more source

Classification of anticancer drugs: an update with FDA- and EMA-approved drugs. [PDF]

Cancer Metastasis Rev
Ostios-Garcia L, Pérez DM, Castelo B, Herradón NH, Zamora P, Feliu J, Espinosa E.   +6 more
europepmc   +1 more source

Impact of antiemetic prophylaxis on reducing trastuzumab deruxtecan dose modifications in HER2+/HER2-low breast cancer. [PDF]

Future Oncol
Shin J, Kim JY, Ahn HK, Ahn JS, Park YH.
europepmc   +1 more source

Revolutionizing cancer treatment: the rise of personalized immunotherapies. [PDF]

Discov Oncol
Fayyaz A, Haqqi A, Khan R, Irfan M, Khan K, Reiner Ž, Sharifi-Rad J, Calina D.   +7 more
europepmc   +1 more source

<i>In Vivo</i> Evaluation of a Self-Excitatory Near-Infrared ImmunoSCIFI Probe. [PDF]

Bioconjug Chem
Gristwood K, Luli S, Blair HJ, Rankin KS, Knight JC.   +4 more
europepmc   +1 more source

Exceptional Response to Trastuzumab Deruxtecan (T-DXd) in HER2-Positive Metastatic Endometrial Cancer. [PDF]

Curr Oncol
Vida R, Bartoletti M, Lerda L, Corsetti S, Scalone S, Calabrò A, Caroli A, Rizzetto M, Zapelloni G, Caccin E, Fucina S, Bortolin G, Cecco S, Baldo P, Pignata S, Califano D, Canzonieri V, Ditto A, Puglisi F.   +18 more
europepmc   +1 more source

Comparison of molecular profiles (Nectin-4 and TROP-2) in upper tract urothelial carcinoma with a positive history of urinary bladder cancer vs. UTUC only in the era of ADCs. [PDF]

BMC Cancer
Kanaan MR, Schmitz J, Braesen JH, Kuczyk MA, Tezval H.   +4 more
europepmc   +1 more source

Advanced cholangiocarcinoma with human epidermal growth factor receptor 2 (HER2) amplification treated with Trastuzumab deruxtecan (T-DXd): A case report. [PDF]

Medicine (Baltimore)
Bao X, Chen Z, Xiong J, Yang Z, Zhang N.
europepmc   +1 more source

Development of ⁵²Mn Labeled Trastuzumab for Extended Time Point PET Imaging of HER2. [PDF]

Mol Imaging Biol
Omweri JM, Saini S, Houson HA, Tekin V, Pyles JM, Parker CC, Lapi SE.   +6 more
europepmc   +1 more source